LY293111 is a potent antagonist of leukotrine B4 repector (BLT1) which inhibits the specific binding of radiolabeled-LTB4 to this receptor (IC50 = 17.6 nM). This further prevents LTB4-induced chemotaxis of neutrophils (IC50 = 6.3 nM). Additional in vitro studies have shown that LY293111 inhibits growth of MiaPaCa-2 and AsPC-1 cell lines and subcutaneous xenografts by inducing apoptosis and S-phase arrest.
1. Jackson, W T., et al., 1999. Pharmacologic actions of the second-generation leukotriene B4 receptor antagonist LY293111: in vitro studies. The Journal of pharmacology and experimental therapeutics. 288(1): 286-94. PMID: 9862783
2. Tong, Wei-Gang., et al., 2002. Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research. 8(10): 3232-42. PMID: 12374694
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.